Effect of database profile variation on drug safety assessment: An analysis of spontaneous adverse event reports of Japanese cases

Kaori Nomura, Kunihiko Takahashi, Yasushi Hinomura, Genta Kawaguchi, Yasuyuki Matsushita, Hiroko Marui, Tatsuhiko Anzai, Masayuki Hashiguchi, Mayumi Mochizuki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The use of a statistical approach to analyze cumulative adverse event (AE) reports has been encouraged by regulatory authorities. However, data variations affect statistical analyses (eg, signal detection). Further, differences in regulations, social issues, and health care systems can cause variations in AE data. The present study examined similarities and differences between two publicly available databases, ie, the Japanese Adverse Drug Event Report (JADER) database and the US Food and Drug Administration Adverse Event Reporting System (FAERS), and how they affect signal detection. Methods: Two AE data sources from 2010 were examined, ie, JADER cases (JP) and Japanese cases extracted from the FAERS (FAERS-JP). Three methods for signals of disproportionate reporting, ie, the reporting odds ratio, Bayesian confidence propagation neural network, and Gamma Poisson Shrinker (GPS), were used on drug-event combinations for three substances frequently recorded in both systems. Results: The two databases showed similar elements of AE reports, but no option was provided for a shareable case identifier. The average number of AEs per case was 1.6±1.3 (maximum 37) in the JP and 3.3±3.5 (maximum 62) in the FAERS-JP. Between 5% and 57% of all AEs were signaled by three quantitative methods for etanercept, infliximab, and paroxetine. Signals identified by GPS for the JP and FAERS-JP, as referenced by Japanese labeling, showed higher positive sensitivity than was expected. Conclusion: The FAERS-JP was different from the JADER. Signals derived from both datasets identified different results, but shared certain signals. Discrepancies in type of AEs, drugs reported, and average number of AEs per case were potential contributing factors. This study will help those concerned with pharmacovigilance better understand the use and pitfalls of using spontaneous AE data.

Original languageEnglish
Pages (from-to)3031-3041
Number of pages11
JournalDrug Design, Development and Therapy
Volume9
DOIs
Publication statusPublished - 2015 Jun 12

Fingerprint

United States Food and Drug Administration
Drug-Related Side Effects and Adverse Reactions
Databases
Safety
Pharmaceutical Preparations
Pharmacovigilance
Paroxetine
Information Storage and Retrieval
Drug Combinations
Odds Ratio
Delivery of Health Care
Food
Psychological Signal Detection

Keywords

  • Drug safety
  • Japan
  • Reporting disproportionality
  • Spontaneous reports system

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Effect of database profile variation on drug safety assessment : An analysis of spontaneous adverse event reports of Japanese cases. / Nomura, Kaori; Takahashi, Kunihiko; Hinomura, Yasushi; Kawaguchi, Genta; Matsushita, Yasuyuki; Marui, Hiroko; Anzai, Tatsuhiko; Hashiguchi, Masayuki; Mochizuki, Mayumi.

In: Drug Design, Development and Therapy, Vol. 9, 12.06.2015, p. 3031-3041.

Research output: Contribution to journalArticle

Nomura, Kaori ; Takahashi, Kunihiko ; Hinomura, Yasushi ; Kawaguchi, Genta ; Matsushita, Yasuyuki ; Marui, Hiroko ; Anzai, Tatsuhiko ; Hashiguchi, Masayuki ; Mochizuki, Mayumi. / Effect of database profile variation on drug safety assessment : An analysis of spontaneous adverse event reports of Japanese cases. In: Drug Design, Development and Therapy. 2015 ; Vol. 9. pp. 3031-3041.
@article{7035077ca8504cd08c834085ba13fddd,
title = "Effect of database profile variation on drug safety assessment: An analysis of spontaneous adverse event reports of Japanese cases",
abstract = "Background: The use of a statistical approach to analyze cumulative adverse event (AE) reports has been encouraged by regulatory authorities. However, data variations affect statistical analyses (eg, signal detection). Further, differences in regulations, social issues, and health care systems can cause variations in AE data. The present study examined similarities and differences between two publicly available databases, ie, the Japanese Adverse Drug Event Report (JADER) database and the US Food and Drug Administration Adverse Event Reporting System (FAERS), and how they affect signal detection. Methods: Two AE data sources from 2010 were examined, ie, JADER cases (JP) and Japanese cases extracted from the FAERS (FAERS-JP). Three methods for signals of disproportionate reporting, ie, the reporting odds ratio, Bayesian confidence propagation neural network, and Gamma Poisson Shrinker (GPS), were used on drug-event combinations for three substances frequently recorded in both systems. Results: The two databases showed similar elements of AE reports, but no option was provided for a shareable case identifier. The average number of AEs per case was 1.6±1.3 (maximum 37) in the JP and 3.3±3.5 (maximum 62) in the FAERS-JP. Between 5{\%} and 57{\%} of all AEs were signaled by three quantitative methods for etanercept, infliximab, and paroxetine. Signals identified by GPS for the JP and FAERS-JP, as referenced by Japanese labeling, showed higher positive sensitivity than was expected. Conclusion: The FAERS-JP was different from the JADER. Signals derived from both datasets identified different results, but shared certain signals. Discrepancies in type of AEs, drugs reported, and average number of AEs per case were potential contributing factors. This study will help those concerned with pharmacovigilance better understand the use and pitfalls of using spontaneous AE data.",
keywords = "Drug safety, Japan, Reporting disproportionality, Spontaneous reports system",
author = "Kaori Nomura and Kunihiko Takahashi and Yasushi Hinomura and Genta Kawaguchi and Yasuyuki Matsushita and Hiroko Marui and Tatsuhiko Anzai and Masayuki Hashiguchi and Mayumi Mochizuki",
year = "2015",
month = "6",
day = "12",
doi = "10.2147/DDDT.S81998",
language = "English",
volume = "9",
pages = "3031--3041",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Effect of database profile variation on drug safety assessment

T2 - An analysis of spontaneous adverse event reports of Japanese cases

AU - Nomura, Kaori

AU - Takahashi, Kunihiko

AU - Hinomura, Yasushi

AU - Kawaguchi, Genta

AU - Matsushita, Yasuyuki

AU - Marui, Hiroko

AU - Anzai, Tatsuhiko

AU - Hashiguchi, Masayuki

AU - Mochizuki, Mayumi

PY - 2015/6/12

Y1 - 2015/6/12

N2 - Background: The use of a statistical approach to analyze cumulative adverse event (AE) reports has been encouraged by regulatory authorities. However, data variations affect statistical analyses (eg, signal detection). Further, differences in regulations, social issues, and health care systems can cause variations in AE data. The present study examined similarities and differences between two publicly available databases, ie, the Japanese Adverse Drug Event Report (JADER) database and the US Food and Drug Administration Adverse Event Reporting System (FAERS), and how they affect signal detection. Methods: Two AE data sources from 2010 were examined, ie, JADER cases (JP) and Japanese cases extracted from the FAERS (FAERS-JP). Three methods for signals of disproportionate reporting, ie, the reporting odds ratio, Bayesian confidence propagation neural network, and Gamma Poisson Shrinker (GPS), were used on drug-event combinations for three substances frequently recorded in both systems. Results: The two databases showed similar elements of AE reports, but no option was provided for a shareable case identifier. The average number of AEs per case was 1.6±1.3 (maximum 37) in the JP and 3.3±3.5 (maximum 62) in the FAERS-JP. Between 5% and 57% of all AEs were signaled by three quantitative methods for etanercept, infliximab, and paroxetine. Signals identified by GPS for the JP and FAERS-JP, as referenced by Japanese labeling, showed higher positive sensitivity than was expected. Conclusion: The FAERS-JP was different from the JADER. Signals derived from both datasets identified different results, but shared certain signals. Discrepancies in type of AEs, drugs reported, and average number of AEs per case were potential contributing factors. This study will help those concerned with pharmacovigilance better understand the use and pitfalls of using spontaneous AE data.

AB - Background: The use of a statistical approach to analyze cumulative adverse event (AE) reports has been encouraged by regulatory authorities. However, data variations affect statistical analyses (eg, signal detection). Further, differences in regulations, social issues, and health care systems can cause variations in AE data. The present study examined similarities and differences between two publicly available databases, ie, the Japanese Adverse Drug Event Report (JADER) database and the US Food and Drug Administration Adverse Event Reporting System (FAERS), and how they affect signal detection. Methods: Two AE data sources from 2010 were examined, ie, JADER cases (JP) and Japanese cases extracted from the FAERS (FAERS-JP). Three methods for signals of disproportionate reporting, ie, the reporting odds ratio, Bayesian confidence propagation neural network, and Gamma Poisson Shrinker (GPS), were used on drug-event combinations for three substances frequently recorded in both systems. Results: The two databases showed similar elements of AE reports, but no option was provided for a shareable case identifier. The average number of AEs per case was 1.6±1.3 (maximum 37) in the JP and 3.3±3.5 (maximum 62) in the FAERS-JP. Between 5% and 57% of all AEs were signaled by three quantitative methods for etanercept, infliximab, and paroxetine. Signals identified by GPS for the JP and FAERS-JP, as referenced by Japanese labeling, showed higher positive sensitivity than was expected. Conclusion: The FAERS-JP was different from the JADER. Signals derived from both datasets identified different results, but shared certain signals. Discrepancies in type of AEs, drugs reported, and average number of AEs per case were potential contributing factors. This study will help those concerned with pharmacovigilance better understand the use and pitfalls of using spontaneous AE data.

KW - Drug safety

KW - Japan

KW - Reporting disproportionality

KW - Spontaneous reports system

UR - http://www.scopus.com/inward/record.url?scp=84933042288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933042288&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S81998

DO - 10.2147/DDDT.S81998

M3 - Article

C2 - 26109846

AN - SCOPUS:84933042288

VL - 9

SP - 3031

EP - 3041

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -